All Type of News
Green Cross regaining ground
Green Cross Holdings said on November 2 it earned 93.4 billion won in the third quarter of 2006, and its operating income and net profit were chalked up 50.2 percent and 107.9 percent, respectively, from a year ago.
...
Anti-impotence drug sets off war among competitors
Competition is about to heat up in the domestic anti-impotence drug market, as Bayer Korea and Chong Kung Dang Pharmaceutical, like the successful strategic alliance of Lilly Korea and Daewoong Pharm, finally agreed t...
742 combined drugs to be in non-NHI reimbursement scheme.
As planned 742 combined drugs are excluded from the NHI reimbursement schedule taking effects from Nov. 1., under which many of them seem to be returned in fear of idle stocks at the pharmacy shelf.
The Drug Revie...
Joint drug logistic projects likely to realize at early next year.
Amid the legislation announcement of the Pharmaceutical Affairs Act related with the establishment of a joint drug logistic center, the joint drug logistic projects that have been driven ambitiously by the wholesale ...
Handok launches Tracleer in pulmonary arterial hypertensionHandok Pharm announced on November 1 that Tracleer tablet (bosentan) is now available upon prescription to all patients in Korea.
In March of this year, the Korea Food and Dr...
|
Kang Han-goo named head of Bayer Schering Pharma in TaiwanBayer HealthCare AG, a subsidiary of Bayer AG in Germany, has recently named Kang Han-goo, executive managing director at Bayer Korea, as the new president of Bayer Schering Pha...
|
Domestic pharmaceutical firms will likely lose momentum under proposed quantity-price linkage system
The government's plan to introduce a system of linking the quantity and quantity of drugs in evaluating drugs to be covered by national insurance will result in discouraging local pharmaceutical firms' will to develop...
Local clinical studies at a level of advanced countries.
To upgrade the local clinical studies the government regulatory plans to reinforce the clinical study inspection and its safety controls, including more educational programs for the study researchers and an establishm...
Government urged to scrap discriminatory policy in new drug pricing system
The Korean government should withdraw its discriminatory policies against domestic pharmaceutical industry, said the Korean Pharmaceutical Association (KPA) said on October 31.
In its statement, the KPA said that t...
KFDA granted sale of Symbicort Smart.
AstraZeneca Korea has received a KFDA approval for the sales of Symbicort (budesonide/formoterol), a combination of an inhaled corticosteroid and long-acting bronchodilator, for the treatment of asthma and Chronic Obs...
